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TO THE EDITOR
We are pleased at the interest that
Kwatra (2011) has shown in our article
‘‘Malignant cutaneous T-cell lympho-
ma cells express IL-17 utilizing the
Jak3/Stat3 signaling pathway’’ (Krejs-
gaard et al., 2011) and welcome the
opportunity to discuss the conclusions
drawn from the study.
Kwatra (2011) argues that because
only the two IL-2 receptor b chain
(IL-2Rb) cytokines, IL-2 and IL-15,
but not the other Jak3-activating cyto-
kines utilizing the common cytokine
receptor g chain (gc) increase the
expression of IL-17, it is misleading to
conclude that the Jak3/signal transducer
and activator of transcription 3 (Stat3)
pathway promotes the malignant ex-
pression of IL-17 in cutaneous T-cell
lymphoma (CTCL). Instead, he suggests
that the conclusion that can be drawn
from the study is that IL-2 and IL-15
mediate IL-17 expression through Jak3
signaling. Of notice, this is in agree-
ment with our statement in this article,
namely that ‘‘Our results show that the
IL-2Rb cytokine-induced expression of
IL-17 is mediated through a Jak3/Stat3-
dependent mechanism’’. Thus, the
question is, can Jak3 also promote the
expression of IL-17 in the absence of
IL-2Rb cytokines?
First of all, the malignant T cells
spontaneously produced low amounts
of IL-17 after cytokine starvation, in-
dicating that IL-17 is not exclusively
regulated by IL-2 and IL-15. Second,
although the activity of Jak3 is greatly
increased after stimulation with IL-2Rb
cytokines, it exhibits constitutive activ-
ity in the malignant CTCL cells even
after cytokine starvation (Krejsgaard et al.,
2006). This is possibly through a cyto-
kine-independent mechanism involving
loss of regulatory control by the protein
tyrosine phosphatases and/or suppres-
sors of cytokine signaling (Zhang et al.,
2000; Brender et al., 2005). Third, Jak3
knockdown by small interfering RNA
inhibited the spontaneous IL-17 produc-
tion. Therefore, we do not think that it is
misleading to conclude that our results
indicate Jak3 promotes the expression of
IL-17 by the malignant T cells.
As Kwatra (2011) points out, we are
aware that WHI-P154 inhibits Jak2 and
Jak3 at comparable concentrations and
that recent data have indicated that CP-
690,550 inhibits Jak1 and Jak2 with
similar affinities as Jak3 (Carbonnelle
et al., 2009; Meyer et al., 2010).
However, because we substantiated
the results obtained using the Jak3
inhibitors by the Jak3-directed small
interfering RNA, we think that it justifi-
able to conclude that Jak3 is involved in
promoting the expression of IL-17. That
said, these data do not exclude that the
expression of IL-17 can also be modu-
lated with other members of the Jak
family.
In the study, we primarily focused on
the role of IL-2Rb cytokines in the
malignant secretion of IL-17 and concur
that further studies are needed to fully
establish if other members of the gc
family can modulate the expression of
IL-17 by the malignant T cells. Never-
theless, our data show that relatively
high concentrations of IL-4, IL-7, IL-9,
and IL-21 do not significantly increase
their secretion of IL-17 in vitro. Of
notice, we have confirmed that IL-21
activates the Jak3/Stat3 pathway in
the malignant T cells with minimal
influence on the expression of IL-17
(data not shown). In addition, we found
that some patients were IL-17 negative
even though the malignant T cells exhi-
bited constitutive activation of Stat3.
Accordingly, as discussed in the article,
the capacity of the Jak3/Stat3 pathway
to promote IL-17 expression seems to
be regulated by additional factors. It is
possible that some cytokines, like IL-21,
not only activate the Jak3/Stat3 path-
way but also activate other pathways
that modulate the Jak3-dependent IL-17
expression. Moreover, it seems likely
that the expression of IL-17 is also
modulated by other signaling pathways
and transcription factors that are often
known to be aberrantly regulated in
CTCL (Sors et al., 2006; Krejsgaard
et al., 2009; Kopp et al., 2010). In our
opinion, the present data suggest that
Jak3 promotes the expression of IL-17
by the malignant CTCL cells both in the
presence and in the absence of IL-2 and
IL-15. Therefore, we conclude in the
article that Jak3 promotes the expres-
sion of IL-17, but we also clearly
highlight that this is regulated by other
factors.
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